Sumitomo Pharma Co., Ltd.'s Form 4 filing
Myovant Sciences Ltd. (MYOV) · filed Aug 24, 2021
- Accession no.
- 0000899243-21-034046
- Filed
- Aug 24, 2021, 5:00 PM ET
- Trade date
- Aug 20-23, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $2.21M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sumitomo Pharma Co., Ltd.CIK 0001446601 | 10% Owner |
| Sumitovant Biopharma Ltd.CIK 0001798244 | 10% Owner |
| Sumitomo Chemical Co., Ltd.CIK 0001798550 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2021 | Common Stock | PPurchaseAcquired | +46,478 | $20.86F2 | +$969,540.38 | 48,823,283 | Indirect | |
| Aug 23, 2021 | Common Stock | PPurchaseAcquired | +25,057 | $22.13F5 | +$554,413.69 | 48,848,340 | Indirect | |
| Aug 23, 2021 | Common Stock | PPurchaseAcquired | +30,390 | $22.45F7 | +$682,322.36 | 48,878,730 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades ranging from $20.32 to $21.27 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F5
The transaction was executed in multiple trades ranging from $21.36 to $22.35 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F7
The transaction was executed in multiple trades ranging from $22.36 to $22.66 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.